Abstract:Chronic hepatitis B is associated with high morbidity and mortality. Chronic hepatitis B requires long‐term management aiming at reduction of the risks of hepatocellular inflammatory necrosis, liver fibrosis, decompensated liver cirrhosis, liver failure, and liver cancer, and improving health‐related quality of life. The Chinese herbal medicine formula Xiao Chai Hu Tang has been used to decrease discomfort and replication of the virus in people with chronic hepatitis B. However, the benefits and harms of Xiao Chai Hu Tang formula have never been established with rigorous review methodology. To assess the benefits and harms of Xiao Chai Hu Tang formula versus placebo or no intervention in people with chronic hepatitis B. We searched The Cochrane Hepato‐Biliary Group Controlled Trials Register, CENTRAL, MEDLINE Ovid, Embase Ovid, and seven other databases to 1 March 2019. We also searched the World Health Organization International Clinical Trials Registry Platform ( www.who.int/ictrp ), ClinicalTrials.gov ( www.clinicaltrials.gov/ ), and the Chinese Clinical Trial Registry for ongoing or unpublished trials to 1 March 2019. We included randomised clinical trials, irrespective of publication status, language, and blinding, comparing Xiao Chai Hu Tang formula versus no intervention or placebo in people with chronic hepatitis B. We included participants of any sex and age, diagnosed with chronic hepatitis B according to guidelines or as defined by the trialists. We allowed co‐interventions when the co‐interventions were administered equally to all the intervention groups. Review authors independently retrieved data from reports and after correspondence with investigators. Our primary outcomes were all‐cause mortality, serious adverse events, and health‐related quality of life. Our secondary outcomes were hepatitis B‐related mortality, hepatitis B‐related morbidity, and adverse events considered 'not to be serious'. We presented the meta‐analysed results as risk ratios (RR) with 95% confidence intervals (CI). We assessed the risks of bias using risk of bias domains with predefined definitions. We used GRADE methodology to evaluate our certainty in the evidence. We included 10 randomised clinical trials with 934 participants, but only five trials with 490 participants provided data for analysis. All the trials compared Xiao Chai Hu Tang formula with no intervention. All trials appeared to have been conducted and published only in China. The included trials assessed heterogeneous forms of Xiao Chai Hu Tang formula, administered for three to eight months. One trial included participants with hepatitis B and comorbid tuberculosis, and one trial included participants with hepatitis B and liver cirrhosis. The remaining trials included participants with hepatitis B only. All the trials were at high risk of bias, and the certainty of evidence for all outcomes that provided data for analyses was very low. We downgraded the evidence by one or two levels because of outcome risk of bias, inconsistency or heterogeneity of results (opposite direction of effect), indirectness of evidence (use of surrogate outcomes instead of clinically relevant outcomes), imprecision of results (the CIs were wide), and publication bias (small sample size of the trials). Additionally, 47 trials lacked the necessary methodological information needed to ensure the inclusion of these trials in our review. None of the included trials aimed to assess clinically relevant outcomes such as all‐cause mortality, serious adverse events, health‐related quality of life, hepatitis B‐related mortality, or hepatitis B‐related morbidity. The effects of Xiao Chai Hu Tang formula on the proportion of participants with adverse events considered 'not to be serious' is uncertain (RR 0.43, 95% CI 0.02 to 11.98; I 2 = 69%; very low‐certainty evidence). Only three trials with 222 participants reported the proportion of people with detectable hepatitis B virus DNA (HBV‐DNA), but the evidence that Xiao Chai Hu Tang formula reduces the presence of HBV‐DNA in the blood (a surrogate outcome) is uncertain (RR 0.62, 95% CI 0.45 to 0.85; I 2 = 0%; very low‐certainty evidence). Only two trials with 160 participants reported the proportion of people with detectable hepatitis B virus e‐antigen (HBeAg; a surrogate outcome) (RR 0.72, 95% CI 0.50 to 1.02; I 2 = 38%; very low‐certainty evidence) and the evidence is uncertain. The evidence is also uncertain for separately reported adverse events considered 'not to be serious'. Funding: two of the 10 included trials received academic funding from government or hospital. None of the remaining eight trials reported information on funding. The clinical effects of Xiao Chai Hu Tang formula for chronic hepatitis B remain unclear. The included trials were small and of low metho -Abstract Truncated-

Therapeutic Efficacy of Anluohuaxian Pill in Treatment of Hepatitis B-related Cirrhosis:a Meta-analysis

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

Efficacy and safety of AnluoHuaxian pills on chronic hepatitis B with normal or minimally elevated alanine transaminase and early liver fibrosis: A randomized controlled trial

Clinical Trail of Decoction of Tonifying Qi Activating Blood and Detoxifcation in the Treatment of Chronic Hepatitis B Patients with Alanine Aminotransferase Less than Two-time upper Limits of Normal Level

Clinical and Experimental Effectiveness of Astragali Compound in the Treatment of Chronic Viral Hepatitis B

Systematic Review on Liuweiwuling Tablets Combined with Nucleotide Analogues in Treatment of Chronic Hepatitis BΔ

An-Luo-Hua-Xian Pill Improves the Regression of Liver Fibrosis in Chronic Hepatitis B Patients Treated with Entecavir

Clinical Effect of Xiaoyao Pill Auxiliary Adefovir Dipivoxil on Patients with Chronic Hepatitis B

[Effects of Anluohuaxianwan on Transforming Growth Factor-Β1 and Related Signaling Pathways in Rats with Carbon Tetrachloride-Induced Liver Fibrosis].

[The Analyse of Effectiveness in HBeAg-positive Chronic Viral Hepatitis B Treated by Adefovir Dipivoxil Combined with Bicyclol].

Systematic evalution of Fuzheng Huayu Capsule combined with Adefovir Dipivoxil in treatment of chronic hepatitis B with hepatic fibrosis

Clinical efficacy and safety of TCM prescriptions combined with nucleoside (acid) analogues in treating chronic hepatitis B: a meta-analysis

Fuzheng Huayu capsule as an adjuvant treatment for HBV-related cirrhosis: A systematic review and meta-analysis.

Comparison of therapeutic efficacy between two Chinese patent drugs for liver fibrosis

Clinical Study on Oral Administration of "ruanjian Huayu Decoction" with External Application of "jiedu Xiaopi Powder" in Treating Early HBV-related Cirrhosis of Blood-Stasis Obstruction

Effect of Anluohuaxian Tablet Combined with Γ-Ifn on Schistosomal Liver Fibrosis

Xiao Chai Hu Tang, a herbal medicine, for chronic hepatitis B.

[Combined anluohuaxianwan and entecavir treatment significantly improve the improvement rate of liver fibrosis in patients with chronic hepatitis B virus infection].

Clinical observation of Rougan Huaxian granule combined with nucleoside antiviral drugs in treatment of patients with decompensated cirrhosis of hepatitis B

Effect of oxymatrine combined with compound salvia miltiorrhiza on serological markers of liver fibrosis, tumor necrosis factor-alpha and leptin levels in patients with chronic hepatitis B

Effect of Antiviral Therapy on the Prognosis of Patients with Chronic Hepatitis B-related Cirrhosis